Physician profile
Joe Su
NPI 1982194262
$540.48
in general payments reported to CMS, 2019-2025
10 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.29 · 2023: $148 · 2024: $197 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $161.51 | 2022-2025 | |
| Abbvie INC. | $135.09 | 2024-2025 | |
| Janssen Biotech, INC. | $78.25 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $31.25 | 2023 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $30.57 | 2023 | Sotyktu |
| Genzyme Corporation | $25.86 | 2023 | |
| Verrica Pharmaceuticals INC. | $24.24 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $19.57 | 2024 | Zoryve |
| Ucb, INC. | $19.41 | 2025 | Bimzelx |
| Strata Skin Sciences, INC. | $14.73 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.